PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
May 04, 2021
May 04, 2021

byprotokinetixp

Exciting things are happening at ProtoKinetix. Our clinical research is driving forward, we’re forming dynamic new partnerships, and we are poised to witness some incredible developments using our patented anti-aging...Read more
Marietta, Ohio, April 22, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced Phase I clinical trials of AAGP® (PKX-001) treated islet cells...Read more
Marietta, Ohio, April 14, 2021 ProtoKinetix, Incorporated (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has engaged a global pharmaceutical company to develop the formulation...Read more
Marietta, Ohio, April 7, 2021                                                                                                             ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the publication of a peer reviewed research paper describing and interpreting the...Read more
Jan 22, 2021
Imagine the ability to fully recover from Type 1 diabetes and no longer live your life according to insulin. Imagine a future where we can overcome blindness. AAGP, the glycopeptide...Read more
Marietta, Ohio, November 24, 2020                                                                                           ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing and interpreting the results...Read more
Oct 30, 2020
The promise of biotechnology stocks to the average investor is the potential for blazing growth and incredible returns. But not every company pays dividends on that promise. Too many times,...Read more
Sep 22, 2020
Dry eye disease (DED) is a multifactorial disease of the ocular surface which results in a spectrum of symptoms and/or signs that affect 5 30% of the population. Download our...Read more
Sep 21, 2020
A 2017 study from the American Optometric Association found that more than 16 million Americans are affected by dry eye disease (DED), also known as dry eye syndrome (DES), including...Read more
Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule